Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28535485 | 0.93 | CTSK (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL1146387 | 0.93 | CTSK (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL28538690 | 0.92 | — | — | |
| SCHEMBL2150746 | 0.92 | EPHX1 (0.31) | — | |
| SCHEMBL28522417 | 0.83 | — | — | |
| SCHEMBL28515970 | 0.83 | — | — | |
| SCHEMBL28518414 | 0.83 | — | — | |
| SCHEMBL28514102 | 0.82 | — | — | |
| SCHEMBL28514415 | 0.81 | — | — | |
| SCHEMBL10835890 | 0.75 | USP2 (0.33) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017044899-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| CN-102369197-B | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines used as ADP receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-11-06 | — | — | CN | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| CN-101765585-A | Antibacterial agent | ACHAOGEN INC | 2010-06-30 | — | — | CN | disclosed |
| CN-1288135-C | Certain 1- (D-cyclopropylglycyl) -4- (piperidin-4-yl) piperazine compounds as inhibitors of the serine protease factor XA | LILLY CO ELI (US) | 2006-12-06 | — | — | CN | disclosed |
| CN-1642914-A | Certain 1- (D-cyclopropylglycyl) -4- (piperidin-4-yl) piperazine compounds as inhibitors of the serine protease factor XA | LILLY CO ELI (US) | 2005-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP4F2 2962/4885CYP4A11 4807/4885 |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | CYP4F2 1901/4885CYP4A11 2490/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CYP4F2 2962/4885CYP4A11 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.